Respiratory Physiotherapy and Neurorehabilitation in Patients With Post-covid19 Sequelae.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05195099 |
Recruitment Status :
Completed
First Posted : January 18, 2022
Last Update Posted : June 29, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The objectives are to reduce dyspnoea, increase exertional capacity, increase vital capacity and respiratory muscle strength.
vital capacity and respiratory muscle strength. In addition to increasing the sensibility of smell and taste, observing if there is a relationship between the decrease of these senses with the senses with appetite and whether appetite has normalised in post-SARS-CoV-2 patients. It is a randomised and blinded experimental study with a control group where the sample recruited will be 30 patients, with a range of of 30 patients, with an age range of 19-42 years, where they carried out an assessment of spirometry, modified Borg dyspnoea scales and modified Medical Research Council (MMRC), Singapure (MMRC), Singapore Smell and Taste Questionnaire (SSTQ) and weekly smell and taste questionnaire.
taste questionnaire.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID-19 Pandemic | Other: respiratory treatment | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Effectiveness of a Physiotherapy Respiratory and Neurorehabilitation Treatment Protocol in Patients With COVID-19. |
Actual Study Start Date : | February 1, 2022 |
Actual Primary Completion Date : | May 1, 2022 |
Actual Study Completion Date : | June 17, 2022 |

Arm | Intervention/treatment |
---|---|
Active Comparator: control group |
Other: respiratory treatment
Respiratory treatment based on aerobic exercise and treatment of the musculature to reduce dyspnoea and increase the capacity for exertion, neurorehabilitative treatment focusing on the sense of smell and taste to on the sense of smell and taste to increase sensitivity in post Covid-19 subjects. |
Experimental: respiratory treatment |
Other: respiratory treatment
Respiratory treatment based on aerobic exercise and treatment of the musculature to reduce dyspnoea and increase the capacity for exertion, neurorehabilitative treatment focusing on the sense of smell and taste to on the sense of smell and taste to increase sensitivity in post Covid-19 subjects. |
- assessment of spirometry. [ Time Frame: 1 year ]modified Borg dyspnoea scales (0, minimum to 10 maximum rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered during six-minute walk testing)
- smell and taste [ Time Frame: 1 week ]smell and taste questionnaire, maximum score (maximum capacity) 40 points. 0 minimum

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 42 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age range between 18 and 42 years.
- patients with respiratory sequelae post Covid-19.
- patients with smell and taste sequelae post Covid-19.
Exclusion Criteria:
- Under 18 years old.
- Over 42 years old.
- Patients not diagnosed with Covid-19 (PCR positive).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05195099
Spain | |
Universidad Católica de Ávila | |
Ávila, Spain, 05005 |
Responsible Party: | JORGE VELAZQUEZ SAORNIL, Principal Investigator, Universidad Católica de Ávila |
ClinicalTrials.gov Identifier: | NCT05195099 |
Other Study ID Numbers: |
14/01/2022 |
First Posted: | January 18, 2022 Key Record Dates |
Last Update Posted: | June 29, 2022 |
Last Verified: | January 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
coronavirus physiotherapies techniques physiotherapies specialty agnosia for taste breathing exercises |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |